• Clear cell renal cell carcinoma
• Computed tomography
• Nomograph
• Prediction model
• Radiomics
• Stage

• NO.2023K121 Quzhou Science and Technology Plan Project

• Clavien–Dindo classification
• complications
• nephrectomy
• renal cell carcinoma
• thrombectomy
• tumor thrombus

• Humans
• Carcinoma, Renal Cell/therapy
• Carcinoma, Renal Cell/epidemiology
• Kidney Neoplasms/therapy
• Kidney Neoplasms/pathology
• Antibodies, Monoclonal, Humanized/therapeutic use
• Immune Checkpoint Inhibitors/therapeutic use
• Chemotherapy, Adjuvant

• Humans
• Kidney Neoplasms/diagnostic imaging
• Positron-Emission Tomography
• Radiopharmaceuticals

• Computed tomography
• Diagnosis
• Multilocular cystic renal neoplasm of low malignant potential
• Renal cysts
• Treatment

• bioinformatics engineering
• clear cell renal clear cell carcinoma
• immune
• immunity therapy
• prognosis
• super-enhancers

• locally advanced renal cell carcinoma
• nomogram
• prognosis
• surveillance, epidemiology, and end results (SEER)
• survival analysis

• Humans
• Aged
• Nomograms
• Carcinoma, Renal Cell
• Databases, Factual
• Multivariate Analysis
• Neoplasms, Second Primary
• Kidney Neoplasms
• Neoplasm Staging
• Prognosis

• DECT
• Genitourinary tract
• Incidentaloma
• Renal stone
• Trauma

• Humans
• Tomography, X-Ray Computed/methods
• Algorithms
• Radiography, Dual-Energy Scanned Projection

• clear cell renal cell carcinoma
• immune activation
• molecular subtyping
• multiomics

• Anhui Provincial University Excellent Scientific Research and Innovation Team Project

• end stage renal failure
• kidney tumours
• renal transplantation

• Male
• Humans
• Middle Aged
• Female
• Carcinoma, Renal Cell/diagnosis
• Retrospective Studies
• Kidney Transplantation
• Kidney
• Kidney Neoplasms/diagnosis

• DNA methylation
• Epigenetic biomarker
• IL18
• Renal cell carcinoma (RCC)
• Tumor immune cell infiltration

Renal cancer is one of the most common malignant tumors with high mortality, and kidney renal clear cell carcinoma (KIRC) is the most common type of renal cancer. We attempted to evaluate the clinical and prognostic significance of Apolipoprotein A1 (APOA1) mRNA and protein in KIRC patients. Clinical data along with RNA-sequencing data were downloaded from UCSC Xena. The Human Protein Atlas database was searched to reveal APOA1 protein expression profiles in KIRC and normal renal tissues. The TIMER database was applied to determine the correlations of APOA1 with immune cells and PD-1 and PD-L1 in KIRC. Ninety-one cases of KIRC patients and 93 healthy controls from our hospital were enrolled for clinical validation. Levels of APOA1 mRNA in KIRC tissues (N = 535) are not only lower than the levels in normal renal tissues (N = 117), but also in paired normal renal tissues (N = 72). High expression of APOA1 mRNA at the time of surgery was correlated with worse overall survival (OS) (HR 1.66; p = 0.037) and disease-free survival (DFS) (HR 1.65; p = 0.047), and APOA1 DNA methylation was linked to worse OS (HR 2.1; p = 0.001) rather than DFS (HR 1.12; p = 0.624) in KIRC patients. Concentrations of preoperative serum APOA1 protein were markedly decreased in KIRC patients compared to healthy controls (p < 0.01), and low levels of APOA1 protein predicted less favorable OS than those with high levels (HR = 2.84, p = 0.0407). APOA1 negatively correlated with various immune cell infiltrates and PD-L1 expression (r = − 0.283, p = 2.74e−11) according to the TIMER database. Low levels of APOA1 mRNA at the time of surgery predict favorable survival in KIRC patients. Our results provide insights to identify a novel prognostic index with great clinical utility.

Transient receptor potential channel 1 (TRPC1) regulates the progression of several cancers, but its clinical implication in renal cell carcinoma (RCC) has not been explored yet. This study aimed to investigate the correlation of TRPC1 with clinical characteristics and prognosis in patients with RCC.

Totally, 177 patients with primary RCC who received surgical resection were retrospectively screened. Their tumor and paired adjacent tissue specimens were retrieved to assess TRPC1 mRNA expression using RT-qPCR and TRPC1 protein expression using immunohistochemistry (IHC).

Both TRPC1 IHC score and TRPC1 mRNA expression were elevated in RCC tissue than in adjacent tissue (both P < 0.001). Meanwhile, both TRPC1 IHC score and TRPC1 mRNA expression in tumor were associated with higher T stage (both P = 0.02) and TNM stage (P = 0.009, P = 0.003, respectively). However, no correlation was found in tumor TRPC1 IHC score or TRPC1 mRNA expression with other tumor properties (all P > 0.05). Besides, the 3-, 5-, and 7-year overall survival (OS) were 81.4, 68.6, and 60.2%, respectively in patients with high tumor TRPC1 protein, while they were 89.3, 82.7, and 76.7%, respectively in patients with low tumor TRPC1 protein. High (vs. low) TRPC1 protein in the tumor was associated with shorter OS (P = 0.017), while high (vs. low) TRPC1 mRNA in the tumor was not correlated with OS (P = 0.144). By the forward stepwise method, TRPC1 protein expression independently predicted poor OS (P = 0.01, hazard ratio = 2.052).

TRPC1 serves as a potential biomarker reflecting tumor features and long-term survival profile in patients with RCC.

• T stage
• TNM stage
• overall survival
• renal cell carcinoma
• transient receptor potential channel 1

Background: In renal clear cell carcinoma, a common cancer of the urinary system, 25–30% patients are metastatic at initial diagnosis and 20–30% patients have a tendency of recurrence and metastasis after local surgery. With the rapid development of tumor immunology, immune agents have brought new directions to tumor therapy. However, no relevant studies have explored the role of immune-related genes in kidney cancer metastasis.

Methods: Co-expressed metastatic immune-related differentially expressed genes (mIR-DEGs) were screened by GSE12606, GSE47352, and immunorelated genes. Then, differential expression analysis, prognostic analysis, and univariate and multivariate Cox regression analysis in KIRC were performed to determine independent prognostic factors associated, and the risk prognostic model was established. The correlation of hub mIR-DEGs with clinicopathological factors, immune invasion, and immune checkpoints was analyzed, and the expression of hub mIR-DEGs and their effect on tumor were re-evaluated by OCLR scores in KIRC.

Results: By comprehensive bioassay, we found that FGF17, PRKCG, SSTR1, and SCTR were mIR-DEGs with independent prognostic values, which were significantly associated with clinicopathological factors and immune checkpoint–related genes. The risk prognostics model built on this basis had good predictive potential. In addition, targeted small molecule drugs, including calmidazolium and sulfasalazine, were predicted for mIR-DEGs. Further experimental results were consistent with the bioinformatics analysis.

Conclusion: This study preliminarily confirmed that FGF17, PRKCG, SSTR1, and SCTR were targeted genes affecting renal cancer metastasis and related immune responses and can be used as potential therapeutic targets and prognostic biomarkers for renal cancer. Preliminary validation found that PRKCG and SSTR1 were consistent with predictions.

• National Natural Science Foundation of China
• Natural Science Foundation of Jiangsu Province

Renal cell carcinoma (RCC) is the most common renal malignant tumour. We evaluated the potential value and dose reduction of virtual non-contrast (VNC) images and virtual monoenergetic images (VMIs) from dual-layer spectral CT (DL-CT) in the diagnosis of RCC.

Sixty-two patients with pathologically confirmed RCC who underwent contrast-enhanced DL-CT were retrospectively analysed. For the comparison between true non-contrast (TNC) and VNC images of the excretory phase, the attenuation, image noise, signal-to-noise ratio (SNR) and subjective image quality of tumours and different abdominal organs and tissues were evaluated. To compare corticomedullary phase images and low keV VMIs (40 to 100 keV) from the nephrographic phase, the attenuation, image noise, SNR and subjective lesion visibility of the tumours and renal arteries were evaluated. For the tumours, significant differences were not observed in attenuation, noise or SNR between TNC and VNC images (p > 0.05). For the abdominal organs and tissues, except for fat, the difference in attenuation was 100% within 15 HU and 96.78% within 10 HU. The subjective image quality of TNC and VNC images was equivalent (p > 0.05). The attenuation of lesions in 40 keV VMIs and renal arteries in 60 keV VMIs were similar to those in the corticomedullary images (p > 0.05). The subjective lesion visibility in low keV VMIs is slightly lower than that in the corticomedullary images (p < 0.05). Using VNC and VMIs instead of TNC and corticomedullary phase images could decrease the radiation dose by 50.5%.

VNC images and VMIs acquired from DL-CT can maintain good image quality and decrease the radiation dose for diagnosis of RCC.

The rhomboids are a family of multi-transmembrane proteins, many of which have been implicated in facilitating tumor progression. Little is yet known, however, about rhomboid-associated biomarkers in cancers. An analysis of such biomarkers could yield important insights into the role of the rhomboids in cancer pathology.

In this study, we carried out the univariate Cox regression analysis and compared gene expression patterns of several rhomboid genes in 30 types of cancers by using The Cancer Genome Atlas (TCGA) database and the methods delineated in Gene Expression Profiling Interactive Analysis (GEPIA). We then used datasets GSE47032, GSE126964, GSE68417 and 75 paired pathological specimens to verify the influences of the rhomboid genes in cancer progression. Moreover, we carried out Weighted Gene Correlation Network Analysis (WGCNA) to investigate gene-related functions and we exploited potential correlations between rhomboid genes expression and immune cell infiltration in cancer tissues. Furthermore, we constructed gene-knockdown cancer cell lines to investigate rhomboid gene functions.

We find that kidney renal clear cell carcinoma (KIRC) disease progression is affected by fluctuations in the expression of a number of the rhomboid family of genes and, more specifically, high levels of RHBDF2 gene expression are a good indicator of poor prognosis of the disease, as patients with high RHBDF2 expression levels exhibit less favorable survival rates compared to those with low RHBDF2 levels. Silencing of the RHBDF2 gene in KIRC cell lines leads to significantly diminished cell proliferation and migration; this is in good agreement with the identification of an enhanced presence of a number of cell growth and migration promoting signaling molecules in KIRC tumors. We found that, although high level of RHBDF2 correlated with increased infiltration of lymphocytes in cancer tissues, artificially overexpressed RHBDF2 led to an inhibition of the activity of the infiltrated immune cells through sustaining PD-L1 protein level. Furthermore, we show that RHBDF2 related cell migration and PD-L1 regulation were potentially mediated by EGFR signaling pathway.

RHBDF2 gene functions are correlated to facilitated renal clear cell carcinoma progression and may serve as a critical prognostic biomarker for the disease.

The online version contains supplementary material available at 10.1186/s12935-021-02277-0.

• Cancer prognosis
• Kidney renal clear cell carcinoma
• PD-L1
• RHBDF2
• Rhomboids

• Anticancer
• Apoptosis
• Cell culture
• Renal cell carcinoma
• Succinic acid

• Anatomical variations
• Embryology
• Inferior vena cava (IVC)
• Thrombus
• Tumour

The dysfunction of myc-related zinc finger protein (MAZ) has been proven to contribute to tumorigenesis and development of multiple cancer types. However, the biological roles and clinical significance of MAZ in clear cell renal carcinoma (ccRCC) remain unclear.

MAZ expression was examined in ccRCC and normal kidney tissue by quantitative real-time PCR and Western blot. Statistical analysis was used to evaluate the clinical correlation between MAZ expression and clinicopathological characteristics to determine the relationship between MAZ expression and the survival of ccRCC patients. The biological roles of MAZ in cells were investigated in vitro using MTT and colony assays. Luciferase reporter assays and chromatin immunoprecipitation (ChIP) were used to investigate the relationship between MAZ and its potential downstream signaling molecules.

MAZ expression is elevated in ccRCC tissues, and higher levels of MAZ were correlated with poor survival of patients with ccRCC. MAZ upregulation elevates the proliferation ability of ccRCC cells in vitro, whereas silencing MAZ represses this ability. Our results further reveal that MAZ promotes cell growth, which is dependent on ERK signaling. Importantly, we found that MAZ positively regulates MAP2K2 expression in ccRCC cells. Mechanistically, MAZ binds to the MAP2K2 promoter and increases MAP2K2 transcription. Furthermore, MAP2K2 levels were shown to be increased in ccRCC tissues and to be associated with a poor prognosis of ccRCC patients. MAP2K2 upregulation activates the ERK signaling pathway and promotes ccRCC progression.

These results reveal that the MAZ/MAP2K2/ERK signaling axis plays a crucial role in promoting ccRCC progression, which suggests the potential therapeutic utility of MAZ in ccRCC.

The online version contains supplementary material available at 10.1186/s12935-021-02020-9.

• Clear cell renal carcinoma
• ERK
• MAP2K2
• MAZ
• Signaling pathway

The relationship between the size of the primary tumor and the prognosis of patients with metastatic renal cell carcinoma (mRCC) is unclear. In this study, we aimed to investigate the significance of the size of the primary tumor in mRCC.

We retrospectively reviewed the data of patients with mRCC who underwent cytoreductive nephrectomy (CN) from 2006 to 2013 in a Chinese center (n = 96) and those in the Surveillance, Epidemiology, and End Results (SEER) database (from 2004 to 2015, n = 4403). Tumors less than 4 cm in size were defined as small. Prognostic factors were analyzed using univariate and multivariate Cox proportional hazards regression analyses.

Patients with small tumors had a longer overall survival than other patients, both in the Chinese cohort (median, 30.0 vs 24.0 months, P = 0.026) and the SEER cohort (median, 43.0 vs 23.0 months, P < 0.001). After adjusting for other significant prognostic factors, small tumor size was still an independent protective factor in the Chinese cohort (adjusted hazard ratio [HR], 0.793; 95% confidence interval [CI]: 0.587–0.998, P = 0.043). In the SEER cohort, multivariate analysis showed that small tumor size was also an independent protective factor (HR, 0.880; 95% CI: 0.654–0.987, P = 0.008). In addition, as a continuous variable, a 1 cm elevation in tumor size translated into a 3.8% higher risk of death (HR, 1.038; 95% CI, 1.029–1.046; P < 0.001).

Patients with small tumors may have a favorable prognosis after CN for mRCC. Although CN is not a standard protocol in mRCC, small tumor size may be a candidate when we are deciding to perform CN because of the potential benefit for OS.

• cytoreductive nephrectomy
• metastasis
• primary tumor size
• prognosis
• renal cell carcinoma

• Collecting system invasion
• Renal cell carcinoma
• Renal pelvis
• Ureter

• brain
• delayed
• late
• metastasis
• nephrectomy
• renal cell carcinoma

• Aged
• Brain Neoplasms/secondary
• Brain Neoplasms/surgery
• Carcinoma, Renal Cell/secondary
• Carcinoma, Renal Cell/surgery
• Craniotomy
• Fatal Outcome
• Humans
• Kidney Neoplasms/pathology
• Kidney Neoplasms/surgery
• Male
• Nephrectomy/methods
• Postoperative Period
• Radiosurgery
• Time Factors

Cereblon (CRBN) is a component of the E3 ubiquitin ligase complex that plays crucial roles in various cellular processes. However, no systematic studies on the expression and functions of CRBN in solid tumors have been conducted to date. Here, we analyzed CRBN expression and its clinical value using several bioinformatic databases. CRBN mRNA expression was downregulated in various cancer types compared to normal cells. Survival analysis demonstrated that overall survival was significantly positively correlated with CRBN expression in some cancer types including lung adenocarcinoma (LUAD), kidney renal clear cell carcinoma (KIRC), and skin cutaneous melanoma (SKCM). CRBN expression was downregulated regardless of clinicopathological characteristics in LUAD and KIRC. Analysis of genes that are commonly correlated with CRBN expression among KIRC, LUAD, and SKCM samples elucidated the potential CRBN-associated mechanisms of cancer progression. Overall, this study revealed the prognostic value of CRBN and its potential associated mechanisms, which may facilitate the development of anti-cancer therapeutic agents.

• cereblon
• kidney renal clear cell carcinoma
• lung adenocarcinoma
• multiomic analysis
• prognostic value
• skin cutaneous melanoma

• CSRNP family
• The Cancer Genome Atlas (TCGA)
• clear cell renal cell carcinoma
• immune infiltration
• prognosis

• CT
• RCC
• indeterminate renal mass
• renal cell carcinoma
• staging

• Nomogram
• SEER
• cancer-specific survival
• chromophobe renal cell carcinoma
• overall survival
• prognosis

• Bioinformatics analysis
• Biomarker
• Renal cell carcinoma
• STATs

• Carcinoma, Renal Cell/genetics
• Carcinoma, Renal Cell/mortality
• Carcinoma, Renal Cell/pathology
• Carcinoma, Renal Cell/therapy
• Computational Biology
• Data Mining
• Drug Resistance, Neoplasm
• Gene Expression Regulation, Neoplastic
• Humans
• Kidney Neoplasms/genetics
• Kidney Neoplasms/mortality
• Kidney Neoplasms/pathology
• Kidney Neoplasms/therapy
• Lymphocytes, Tumor-Infiltrating
• MicroRNAs/genetics
• MicroRNAs/metabolism
• Prognosis
• Protein Interaction Mapping
• Protein Kinases/genetics
• RNA, Messenger/metabolism
• STAT Transcription Factors/genetics
• STAT Transcription Factors/metabolism
• Signal Transduction
• Transcription Factors/genetics

•RCC is the most common type of renal cancer. •RCC is capable of passing through the renal vein into the IVC. •Surgical resection requiring cardiopulmonary bypass is currently the only curative treatment. •Metastatic RCC tumor spread into the heart is a poor long-term prognostic factor.

• Renal cell carcinoma
• Secondary cardiac tumor
• Transesophageal echocardiography

• TKI
• hypertension
• renal cancer

• Adenoma, Oxyphilic/metabolism
• Adenoma, Oxyphilic/pathology
• Biomarkers, Tumor/analysis
• Carcinoma, Renal Cell/metabolism
• Carcinoma, Renal Cell/pathology
• Claudins/analysis
• Humans
• Immunohistochemistry/methods
• In Situ Hybridization, Fluorescence
• Keratin-7/analysis
• Kidney Neoplasms/metabolism
• Kidney Neoplasms/pathology
• Proto-Oncogene Proteins c-kit/analysis
• Sensitivity and Specificity

• Diagnostic imaging
• Neoangiogenesis
• Positron-emission tomography
• Prostate-specific membrane antigen
• Renal cell carcinoma
• Response assessment

• Antigens, Surface/metabolism
• Antineoplastic Agents/therapeutic use
• Carcinoma, Renal Cell/diagnostic imaging
• Carcinoma, Renal Cell/drug therapy
• Carcinoma, Renal Cell/metabolism
• Glutamate Carboxypeptidase II/metabolism
• Humans
• Kidney Neoplasms/diagnostic imaging
• Kidney Neoplasms/drug therapy
• Kidney Neoplasms/metabolism
• Neoplasm Staging
• Positron Emission Tomography Computed Tomography/methods
• Radiopharmaceuticals
• Treatment Outcome

Accurate detection of lymph node involvement on pre-operative imaging in patients diagnosed with renal cell carcinoma (RCC) is critical for determination of disease stage, one of the most significant prognostic factors in RCC. The presence of lymph node involvement in RCC doubles a patient’s risk of distant metastasis and significantly reduces their 5-year survival. Currently, lymph node involvement in patients with RCC is evaluated with numerous modalities, with rapid advancements occurring across these modalities. The purpose of this study was to evaluate the advantages and disadvantages of each modality and utilize sensitivities and specificities to determine the highest performing modalities for accurate lymph node involvement in renal cancer. A comprehensive computer-based literature search of full-length original research English language studies of human subjects with biopsy-proven RCC was performed to evaluate publications on the diagnostic performance of color Doppler sonography (CDS), magnetic resonance imaging (MRI), lymphotrophic nanoparticle enhanced MRI (LNMRI), multidetector-row computed tomography (MDCT), F-fluoro-2-deoxyglucose positron emission tomography (FDG-PET), and PET/CT for evaluation of lymph node status in kidney cancers in articles that were published prior to May 2018. Limited studies were available for evaluating CDS performance for determination of lymph node involvement in renal cancer. While CT is the most common modality for nodal staging, due to its availability and relatively low expense, it did not demonstrate the highest performance of the modalities examined for determination of lymph node status in patients with RCC. Of the modalities examined, MRI demonstrated the highest sensitivity (92–95.7%) for detection of lymph node involvement in RCC. Studies of lymph node involvement in RCC using both MRI and CT indicated that using the current diameter criteria (greater than 1 cm) for determination of positive lymph nodes should be re-evaluated as micro-metastases are frequently overlooked. Studies evaluating lymph node involvement with FDG-PET had the highest specificity (100%), indicating FDG-PET is the preferred modality for confirming lymph node involvement and extent of involvement. However, due to the low sensitivity of FDG-PET, clinicians should be skeptical of negative reports of lymph node involvement in RCC patients. Further studies examining determination of lymph node involvement in renal cancer across modalities are greatly needed, current literature suggests utilizing a combination of MRI and FDG-PET may offer the highest accuracy.

• Imaging
• kidney cancer
• metastatic lymph node
• renal cell carcinoma (RCC)

Renal cell carcinoma (RCC) is frequently associated with paraneoplastic inflammatory syndrome (PIS). This study aimed at exploring the connections between the survival rate and specific gene alterations and the potential mechanism.

We retrospectively studied 69 surgical RCC cases from August 2014 to February 2016, including 18 cases of clear cell RCC (ccRCC) demonstrating elevated pretreatment serum C-reactive protein (CRP, Group A). Twelve of the 18 cases were symptomized with febrile episode. We also selected 49 cases of ccRCC with normal pretreatment CRP (Group B). Using 22 microsatellite markers, we compared the incidence of loss of heterozygosity (LOH) between Group A and Group B. All statistical tests are two-sided.

The 3p LOH was common in both Group A (89%) and Group B (92%). The frequency of 14q LOH in Group A (16 of 18) was higher than Group B (4 of 49, χ² = 40.97 P < 0.0001). The 3p and 14q LOH were the characteristics of ccRCC with elevated acute phase reactants, including PIS, regardless of the presence of metastasis. On the contrary, 14q LOH was a rare genomic alternation in advanced-staged ccRCC without PIS. The overall survival of patients with elevated CRP (33.3%) was lower than its counterparts (6.1%, hazard ratio=1.852, P < 0.0001) in Kaplan-Meier curve.

The results imply that the disruption of a 14q gene(s) might result in not only the inflammatory manifestations in the tumor host but also the poor survival rate as well. The isolation of the gene(s) on 14q might be a vital goal in the treatment of PIS-associated RCC.

Current studies indicated that PCDH17 functions as a tumor suppressor, which is frequently inactivated by aberrant promoter methylation in urologic tumors. The main purpose of this study was to investigate the methylation status of PCDH17 in serum and its clinical significance in renal cell carcinoma (RCC).

The methylation status of PCDH17 in serum samples of 142 RCC patients and 34 controls was evaluated by methylation-specific PCR (MSP). Then we correlated PCDH17 methylation status with the clinicopathologic features of RCC patients and patient outcomes.

We found that PCDH17 was more frequently methylated in RCC patients than in controls. Moreover, PCDH17 methylation in serum was significantly correlated with advanced stage (p=0.044), higher grade (p=0.019), lymph node metastasis (p=0.008) and tumor progression (p<0.001). In addition, patients with methylated PCDH17 had shorter progression-free survival (p<0.001) and overall survival (p=0.017) than patients without, and PCDH17 methylation in serum was an independent prognostic factor for worse progression-free survival (HR: 4.215, 95% CI: 1.376–9.032, p<0.001) and overall survival (HR: 5.092, 95% CI: 1.149–12.357, p=0.046) of patients with RCC.

The present study indicates that PCDH17 methylation in serum is a frequent event in RCC and associated with risk factors of poor outcomes. Moreover, PCDH17 methylation in serum is a potential prognostic biomarker for patients with RCC after surgery.

• Bladder urothelial carcinoma
• CT
• MRI
• PET
• Prostate adenocarcinoma
• Renal cell carcinoma

• Female
• Humans
• Magnetic Resonance Imaging/methods
• Male
• Positron-Emission Tomography/methods
• Urogenital Neoplasms/diagnosis
• Urogenital Neoplasms/diagnostic imaging
• Urogenital Neoplasms/therapy

• ZIA BC011351-01 Intramural NIH HHS

• EphA5
• clear cell renal cell carcinoma
• receptor tyrosine kinase
• renal cell carcinoma

• International Renal Cell Carcinoma-Venous Thrombus Consortium
• Novick staging
• Quandali index
• anticoagulation
• bleeding
• cardiopulmonary bypass
• coagulopathy
• computed tomography
• deep hypothermic circulatory arrest
• embolic burden
• fluorodeoxyglucose
• handoffs
• inferior vena cava
• inhaled epoprostenol
• intensive care unit
• magnetic resonance imaging
• positron emission tomography
• postinfarction syndrome
• pulmonary embolism
• renal artery embolization
• renal cell carcinoma
• right atrium
• right ventricular failure
• team dynamics
• transesophageal echocardiography
• transfusion
• tumor levels
• tumor thrombus
• venovenous bypass

• Cervical cancer
• Endometrial cancer
• MR imaging
• Ovarian cancer
• PET
• PET-MR

• Female
• Genital Neoplasms, Female/diagnostic imaging
• Genitalia, Female/diagnostic imaging
• Humans
• Magnetic Resonance Imaging/methods
• Male
• Multimodal Imaging/methods
• Positron-Emission Tomography/methods
• Urogenital Neoplasms/diagnostic imaging
• Urogenital System/diagnostic imaging

• Hemangiopericytomas
• Mesenchymal tumor
• Solitary fibrous tumor